|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2
|
Hernandez-Gea V, Toffanin S, Friedman SL
and Llovet JM: Role of the microenvironment in the pathogenesis and
treatment of hepatocellular carcinoma. Gastroenterology.
144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
4
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanda M, Nomoto S, Nishikawa Y, Sugimoto
H, Kanazumi N, Takeda S and Nakao A: Correlations of the expression
of vascular endothelial growth factor B and its isoforms in
hepatocellular carcinoma with clinico-pathological parameters. J
Surg Oncol. 98:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanyal AJ, Yoon SK and Lencioni R: The
etiology of hepatocellular carcinoma and consequences for
treatment. Oncologist. 15:14–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khare S, Zhang Q and Ibdah JA: Epigenetics
of hepatocellular carcinoma: Role of microRNA. World J
Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Villanueva A, Hoshida Y, Toffanin S,
Lachenmayer A, Alsinet C, Savic R, Cornella H and Llovet JM: New
strategies in hepatocellular carcinoma: genomic prognostic markers.
Clin Cancer Res. 16:4688–4694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seitz HK and Stickel F: Risk factors and
mechanisms of hepatocarcinogenesis with special emphasis on alcohol
and oxidative stress. Biol Chem. 387:349–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levental KR, Yu H, Kass L, Lakins JN,
Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W,
Yamauchi M, Gasser DL and Weaver VM: Matrix crosslinking forces
tumor progression by enhancing integrin signalling. Cell.
139:891–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yates LR and Campbell PJ: Evolution of the
cancer genome. Nat Rev Genet. 13:795–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coulon S, Heindryckx F, Geerts A, Van
Steenkiste C, Colle I and Van Vlierberghe H: Angiogenesis in
chronic liver disease and its complications. Liver Int. 31:146–162.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sawan C, Vaissiere T, Murr R and Herceg Z:
Epigenetic drivers and genetic passengers on the road to cancer.
Mutat Res. 642:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanda M, Nomoto S, Okamura Y, Nishikawa Y,
Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of
metallothionein 1G as a methylated tumor suppressor gene in human
hepatocellular carcinoma using a novel method of double combination
array analysis. Int J Oncol. 35:477–483. 2009.
|
|
18
|
Dango S, Mosammaparast N, Sowa ME, Xiong
LJ, Wu F, Park K, Rubin M, Gygi S, Harper JW and Shi Y: DNA
unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA
alkylation repair and cancer cell proliferation. Mol Cell.
44:373–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Youngblood B, Oestreich KJ, Ha SJ,
Duraiswamy J, Akondy RS, West EE, et al: Chronic virus infection
enforces demethylation of the locus that encodes PD-1 in
antigen-specific CD8(+) T cells. Immunity. 35:400–412.
2011.PubMed/NCBI
|
|
20
|
Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung
G and Park YN: Aberrant CpG island hypermethylation in dysplastic
nodules and early HCC of hepatitis B virus-related human multistep
hepatocarcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lao V and Grady W: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan Y, Wang J, Li J, Wang L, Li M, Yang
Z, Zhang C and Dai JL: Frequent epigenetic inactivation of spleen
tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer
Res. 12:6687–6695. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moribe T, Iizuka N, Miura T, Kimura N,
Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T and
Oka M: Methylation of multiple genes as molecular markers for
diagnosis of a small, well-differentiated hepatocellular carcinoma.
Int J Cancer. 125:388–397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanda M, Nomoto S, Oya H, Takami H, Hibino
S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, Asai M,
Fujii T, Sugimoto H and Kodera Y: Downregulation of DENND2D
by promoter hypermethylation is associated with early recurrence of
hepatocellular carcinoma. Int J Oncol. 44:44–52. 2014.
|
|
25
|
Shan Z, Parker T and Wiest JS: Identifying
novel homozygous deletions by microsatellite analysis and
characterization of tumor suppressor candidate 1 gene, TUSC1, on
chromosome 9p in human lung cancer. Oncogene. 23:6612–6620. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang XR, Liang X, Pfeiffer RM, Wheeler W,
Maeder D, Burdette L, Yeager M, Chanock S, Tucker MA and Goldstein
AM: Associations of 9p21 variants with cutaneous malignant
melanoma, nevi, and pigmentation phenotypes in melanoma-prone
families with and without CDKN2A mutations. Fam Cancer. 9:625–633.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shan Z, Shakoori A, Bodaghi S, Goldsmith
P, Jin J and Wiest JS: TUSC1, a putative tumor suppressor gene,
reduces tumor cell growth in vitro and tumor growth in vivo. PLoS
One. 8:e661142013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC TNM classification of malignant tumours. 7th edition.
Wiley-Liss; New York: 2009
|
|
29
|
Takai D and Jones PA: Comprehensive
analysis of CpG islands in human chromosomes 21 and 22. Proc Natl
Acad Sci USA. 99:3740–3745. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takai D and Jones PA: The CpG island
searcher: a new WWW resource. In Silico Biol. 3:235–240.
2003.PubMed/NCBI
|
|
31
|
Mead LJ, Gillespie MT, Hung JY, Rane US,
Rayeroux KC, Irving LB and Campbell LJ: Frequent loss of
heterozygosity in early non-small cell lung cancers at chromosome
9p21 proximal to the CDKN2a gene. Int J Cancer. 71:213–217. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wiest JS, Franklin WA, Otstot JT, Forbey
K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S,
Sidransky D, Saccomanno G, Fountain JW and Anderson MW:
Identification of a novel region of homozygous deletion on
chromosome 9p in squamous cell carcinoma of the lung: the location
of a putative tumor suppressor gene. Cancer Res. 57:1–6.
1997.PubMed/NCBI
|
|
33
|
Sheu JC, Lin YW, Chou HC, Huang GT, Lee
HS, Lin YH, Huang SY, Chen CH, Wang JT, Lee PH, Lin JT, Lu FJ and
Chen DS: Loss of heterozygosity and microsatellite instability in
hepatocellular carcinoma in Taiwan. Br J Cancer. 80:468–476. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pollock P, Welch J and Hayward N: Evidence
for three tumor suppressor loci on chromosome 9p involved in
melanoma development. Cancer Res. 61:1154–1161. 2001.PubMed/NCBI
|
|
35
|
Cairns P, Polascik TJ, Eby Y, Tokino K,
Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter
J, Buckler A, Gabrielson E, Tockman M, Cho K, Hedrick L, Bova G,
Isaacs W, Koch W, Schwab D and Sidransky D: Frequency of homozygous
deletion at p16/CDKN2 in primary human tumours. Nat Genet.
11:210–212. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jones PA: Functions of DNA methylation:
islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maunakea AK, Nagarajan RP, Bilenky M,
Ballinger TJ, D’Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C,
Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K,
Heine VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJ,
Haussler D, Marra MA, Hirst M, Wang T and Costello JF: Conserved
role of intragenic DNA methylation in regulating alternative
promoters. Nature. 466:253–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Flanagan J and Wild L: An epigenetic role
for noncoding RNAs and intragenic DNA methylation. Genome Biol.
8:3072007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lorincz M, Dickerson D, Schmitt M and
Groudine M: Intragenic DNA methylation alters chromatin structure
and elongation efficiency in mammalian cells. Nat Struct Mol Biol.
11:1068–1075. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ball M, Li JB, Gao Y, Lee JH, LeProust EM,
Park IH, Xie B, Daley GQ and Church GM: Targeted and genome-scale
strategies reveal gene-body methylation signatures in human cells.
Nat Biotechnol. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
